CJC-1295 & Hexarelin Blend
A high-potency research blend combining CJC-1295 (Mod GRF 1-29) with hexarelin, the most potent GHRP available, for maximum GH pulse amplitude.
Community Rating
No ratings yet
⚠ Research & Educational Use Only. CJC-1295 & Hexarelin Blend is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Maximum GH pulse amplitude (hexarelin is the most potent GHRP)
- Synergistic GHRHR + GHS-R1a dual mechanism
- Hexarelin cardiac research application alongside GH release
- CJC-1295 & Hexarelin Blend is not FDA-approved for human use. It is a research chemical for scientific study only.
Research At a Glance
- Maximum GH pulse amplitude (hexarelin is the most potent GHRP)
- Synergistic GHRHR + GHS-R1a dual mechanism
- Hexarelin cardiac research application alongside GH release
- Strong IGF-1 response
What is CJC-1295 & Hexarelin Blend?
Tap any underlined term for an instant definition.
CJC-1295 & Hexarelin Blend combines CJC-1295 (no DAC) with hexarelin, the most potent GHRP in the GHS family. Hexarelin produces the highest GH pulse amplitudes of any GHRP but has a faster desensitization profile, requiring cycling to maintain efficacy.
What It Is
- CJC-1295 (no DAC): GHRH analogue for pulsatile GHRHR activation
- Hexarelin: the most potent GHRP, producing GH pulses that exceed GHRP-2 and GHRP-6 at equivalent doses; also has documented cardiac cytoprotective effects independent of GH receptor
- High-potency combination for maximum GH axis stimulation
How It Works
- Standard GHRH + GHRP dual-receptor synergy
- Hexarelin's GHS-R1a potency produces the largest GH pulses of any GHRP combination at equivalent doses
- Hexarelin also binds the CD36 scavenger receptor, mediating cardiovascular effects that are GH-receptor independent
- Desensitization: hexarelin downregulates its own receptor faster than other GHRPs; use in cycles of 4-6 weeks with 2-4 week breaks
Key Research Findings
- GH amplitude: Highest of any GHRP at equivalent doses; GH peaks up to 80-100 ng/mL reported in some studies
- Cardiac cytoprotection: Hexarelin reduced infarct size by 30-40% in MI models independent of GH receptor
- Desensitization: Significant GH response reduction after 2-4 weeks of continuous daily use; cycling mandatory
Dosing From the Literature
- CJC-1295 (no DAC) 100-200 mcg + hexarelin 50-100 mcg per injection
- Lower hexarelin doses (50 mcg) reduce cortisol/prolactin side effects while retaining synergistic GH benefit
- Cycle hexarelin 4-6 weeks on, 2-4 weeks off
Storage and Handling
- Lyophilised: 2-8 degrees C; 24 months
- Reconstituted: 2-8 degrees C; use within 30 days
Key Research Benefits
Documented effects observed in preclinical and clinical studies on CJC-1295 & Hexarelin Blend. See all Peptide Blends peptides for comparison.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
Subcutaneous injection. Hexarelin requires cycling due to rapid receptor desensitization.
Explore Further
Quick Reference
More in Peptide Blends
- Sermorelin & Ipamorelin Blend
- Sermorelin & GHRP-2 Blend
- Sermorelin & GHRP-6 Blend
- Sermorelin & GHRP-6 & GHRP-2 Triple Blend
Research Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.